Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK.
Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France.
Molecules. 2022 Apr 28;27(9):2816. doi: 10.3390/molecules27092816.
Two analogues of tolcapone where the nitrocatechol group has been replaced by a 1-hydroxy-2(1)-pyridinone have been designed and synthesised. These compounds are expected to have a dual mode of action both beneficial against Parkinson's disease: they are designed to be inhibitors of catechol -methyl transferase, which contribute to the reduction of dopamine in the brain, and to protect neurons against oxidative damage. To assess whether these compounds are worthy of biological assessment to demonstrate these effects, measurement of their pa and stability constants for Fe(III), in silico modelling of their potential to inhibit COMT and blood-brain barrier scoring were performed. These results demonstrate that the compounds may indeed have the desired properties, indicating they are indeed promising candidates for further evaluation.
设计并合成了托卡朋的两种类似物,其中硝基儿茶酚基团被 1-羟基-2(1)-吡啶酮取代。这些化合物有望具有双重作用模式,对帕金森病均有益:它们被设计为儿茶酚-O-甲基转移酶的抑制剂,有助于减少大脑中的多巴胺,并且可以保护神经元免受氧化损伤。为了评估这些化合物是否具有进行生物学评估以证明这些作用的价值,对其与 Fe(III)的帕值和稳定常数进行了测量,对其抑制 COMT 的潜力进行了计算机模拟,还对其血脑屏障评分进行了评估。这些结果表明,这些化合物确实可能具有所需的性质,这表明它们确实是进一步评估的有希望的候选物。